

Date: 12th July, 2023

BSE Limited

Corporate Relation Department Phiroze Jeejeeboi Towers, Dalal Street, Mumbai - 400001. Scrip Code: 524404

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex,
Bandra (East), Mumbai - 400051.
Symbol: MARKSANS

PRESS RELEASE

Dear Sirs,

Enclosed herewith kindly find a Press Release of the Company dated 12th July, 2023.


For Marksans Pharma Limited

Harshavardhan Panigrahi Company Secretary

Enclosed as above.

CIN: L24110MH1992PLC066364

www.marksanspharma.com



Marksans announces FDA approval of OTC equivalent of Advil[®] Dual Action Tablets

Mumbai, July 12, 2023 – Marksans Pharma Ltd. (NSE: MARKSANS; BSE:524404), a leading provider of consumer self-care products, is pleased to announce that it has received final approval from the US Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg, over the counter ("OTC") bioequivalent of Advil Dual Action Tablets 250 mg/125 mg.

The Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC) are bioequivalent to the reference listed drug (RLD), Advil Dual Action of GlaxoSmithKline Consumer Healthcare Holdings (US) LLC. Advil Dual Action was first available as an over-the-counter drug in 2020.

The pivotal approval, Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg provides relief for multiple pain-related symptoms by combining two powerful ingredients indicated for OTC pain relief, ibuprofen and acetaminophen. Ibuprofen works through the body targeting pain at the source while Acetaminophen blocks pain signal to the brain. The innovation takes these two powerful pain fighting ingredients and combines them into one tablet to offer fast, strong pain relief. The company plans to launch the product immediately.

Commenting on the approval, Mark Saldanha, Managing Director of the Company said "We are committed to expanding our portfolio in OTC Pain Management, this approval further demonstrates our regulatory and manufacturing capabilities and our strength to follow a focused growth approach. We will continue to work diligently towards sustaining this momentum in the coming quarters."

Disclaimer

Certain statements in this press release concerning our future growth prospects may be forward-looking statements, which involve several risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The company's results may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; the extent and duration of the effects of the COVID-19 pandemic; litigation and investigations; business development transactions; economic conditions; and changes in laws and regulations, including health care reform. The company undertakes no duty to update forward-looking statements except as required by applicable law.



About Marksans Pharma:

Marksans Pharma Ltd. (www.marksanspharma.com) headquartered in Mumbai, India is engaged in the Research, Manufacturing & Marketing of generic pharmaceutical formulations in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA, and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Antidiabetic, Pain Management, Gastroenterological, and Anti-allergies. The company is marketing these products globally.

Contact Information Jitendra Sharma, CFO Marksans Pharma Ltd Tel: +91 22 40012000 ir@marksanspharma.com

Registered Office

11th Floor, "GRANDEUR" Off Veera Desai Extension Road Oshiwara, Andheri West Mumbai, Maharashtra, 400 053

Telephone: +91 224001 2000

Fax: +91 224001 2011

CIN: L24110MH1992PLC066364

ISIN: INE750C01026 NSE Code: MARKSANS BSE CODE: 524404

Website: http://www.marksanspharma.com

